Literature DB >> 14982883

Somatic inactivation of Nf1 in hematopoietic cells results in a progressive myeloproliferative disorder.

Doan T Le1, Namie Kong, Yuan Zhu, Jennifer O Lauchle, Abigail Aiyigari, Benjamin S Braun, Endi Wang, Scott C Kogan, Michelle M Le Beau, Luis Parada, Kevin M Shannon.   

Abstract

The NF1 tumor suppressor gene encodes a guanosine triphosphotase (GTPase)-activating protein that negatively regulates Ras signaling and is inactivated in a subset of juvenile myelomonocytic leukemias (JMMLs). Adoptive transfer of fetal liver cells from Nf1 mutant mice models JMML; however, this system has important limitations as a platform for performing biologic and preclinical studies. We have exploited the interferon-inducible Mx1-Cre transgene to ablate a conditional mutant Nf1 allele in hematopoietic cells. Somatic inactivation of Nf1 induces a myeloproliferative disorder with 100% penetrance that is associated with a sub-acute clinical course, tissue infiltration by myeloid cells, hypersensitivity to granulocyte-macrophage colony stimulating factor, hyperproliferation, and resistance to apoptosis. These Mx1-Cre, Nf1(flox/flox) mice establish a tractable experimental model for testing therapeutics and for identifying mutations that cooperate with hyperactive Ras in myeloid leukemogenesis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14982883     DOI: 10.1182/blood-2003-08-2650

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  86 in total

Review 1.  Mechanistic and Preclinical Insights from Mouse Models of Hematologic Cancer Characterized by Hyperactive Ras.

Authors:  Anica Wandler; Kevin Shannon
Journal:  Cold Spring Harb Perspect Med       Date:  2018-04-02       Impact factor: 6.915

2.  Dose-dependent effects of focal fractionated irradiation on secondary malignant neoplasms in Nf1 mutant mice.

Authors:  Jean L Nakamura; Connie Phong; Emile Pinarbasi; Scott C Kogan; Scott Vandenberg; Andrew E Horvai; Bruce A Faddegon; Dorothea Fiedler; Kevan Shokat; Benjamin T Houseman; Richard Chao; Russell O Pieper; Kevin Shannon
Journal:  Cancer Res       Date:  2011-01-01       Impact factor: 12.701

3.  Leukemogenic Ptpn11 causes fatal myeloproliferative disorder via cell-autonomous effects on multiple stages of hematopoiesis.

Authors:  Gordon Chan; Demetrios Kalaitzidis; Tatiana Usenko; Jeffery L Kutok; Wentian Yang; M Golam Mohi; Benjamin G Neel
Journal:  Blood       Date:  2009-01-29       Impact factor: 22.113

Review 4.  Harnessing preclinical mouse models to inform human clinical cancer trials.

Authors:  David H Gutmann; Kim Hunter-Schaedle; Kevin M Shannon
Journal:  J Clin Invest       Date:  2006-04       Impact factor: 14.808

5.  A microenvironment-induced myeloproliferative syndrome caused by retinoic acid receptor gamma deficiency.

Authors:  Carl R Walkley; Gemma Haines Olsen; Sebastian Dworkin; Stewart A Fabb; Jeremy Swann; Grant A McArthur; Susan V Westmoreland; Pierre Chambon; David T Scadden; Louise E Purton
Journal:  Cell       Date:  2007-06-15       Impact factor: 41.582

6.  High-throughput sequencing screen reveals novel, transforming RAS mutations in myeloid leukemia patients.

Authors:  Jeffrey W Tyner; Heidi Erickson; Michael W N Deininger; Stephanie G Willis; Christopher A Eide; Ross L Levine; Michael C Heinrich; Norbert Gattermann; D Gary Gilliland; Brian J Druker; Marc M Loriaux
Journal:  Blood       Date:  2008-12-15       Impact factor: 22.113

7.  Ras-Mek-Erk signaling regulates Nf1 heterozygous neointima formation.

Authors:  Brian K Stansfield; Waylan K Bessler; Raghuveer Mali; Julie A Mund; Brandon D Downing; Reuben Kapur; David A Ingram
Journal:  Am J Pathol       Date:  2013-11-07       Impact factor: 4.307

8.  EWS/FLI-1 induces rapid onset of myeloid/erythroid leukemia in mice.

Authors:  Enrique C Torchia; Kelli Boyd; Jerold E Rehg; Chunxu Qu; Suzanne J Baker
Journal:  Mol Cell Biol       Date:  2007-09-17       Impact factor: 4.272

9.  Sustained MEK inhibition abrogates myeloproliferative disease in Nf1 mutant mice.

Authors:  Tiffany Chang; Kimberly Krisman; Emily Harding Theobald; Jin Xu; Jon Akutagawa; Jennifer O Lauchle; Scott Kogan; Benjamin S Braun; Kevin Shannon
Journal:  J Clin Invest       Date:  2012-12-10       Impact factor: 14.808

10.  High-resolution single-nucleotide polymorphism array-profiling in myeloproliferative neoplasms identifies novel genomic aberrations.

Authors:  Frank Stegelmann; Lars Bullinger; Martin Griesshammer; Karlheinz Holzmann; Marianne Habdank; Susanne Kuhn; Carmen Maile; Stefanie Schauer; Hartmut Döhner; Konstanze Döhner
Journal:  Haematologica       Date:  2009-12-16       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.